['melanoma']
['temozolomide plus cisplatin', 'high-dose ifn-a2b']

        Inclusion Criteria:

          1. Age more than 18 years;

          2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;

          3. Pathologically confirmed diagnosis of mucosal melanoma;

          4. Completely resected primary tumor (once regional lymph nodes were involved, diagnosed
             by clinical or imaging examinations, lymphadenectomy was conducted);

          5. No prior systemic adjuvant therapy or regional radiotherapy;

          6. No evidence of distant metastatic disease evaluated by means of lymph nodes
             ultrasound, endoscopy, and ultrasound of anorectum and genitourinary tract,
             single-photon emission computed tomography (CT) of bone, and whole-body spiral CT or
             positron emission tomography-CT (PET-CT);

          7. Normal bone marrow function; and adequate liver and renal function [including white
             blood cell (WBC) count > 3,000/mm^3;absolute neutrophil count > 1,500/mm^3; platelets
             >100,000/mm^3; serum creatinine less than two times of the upper limit of normal
             (ULN); bilirubin less than 1.5 times of ULN; aspartate aminotransferase (AST) and
             alanine aminotransferase (ALT) less than 2.5 times of ULN; international normalized
             ratio less than 1.5 times of ULN; and partial thromboplastin time less than ULN].

        Exclusion Criteria:

          1. Cutaneous melanoma or ocular melanoma or melanoma of unknown primary site;

          2. Incomplete resection or primary tumor unable to be resected;

          3. A second cancer diagnosis;

          4. Definite medical history of cirrhoses of the liver or autoimmune diseases;

          5. Severe depression; and pregnant or lactating female.
      